德州金蝶软件_德州金蝶_德州财务软件_德州-德州思亿信息技术有限

欢迎访问德州思亿信息技术有限网站首页,德州思亿信息技术有限主营:德州金蝶软件,德州金蝶,德州财务软件,德州进销存软件;地址:天虹广场1518

OX产业网 - OX价格、OX行情与OX资讯服务平台 - 生意社OX频道

生意社OX频道-OX价格与OX行情服务平台-OX产业网

招飞智询管理平台

暂无描述...

锡林郭勒盟民族事务委员会

锡林郭勒盟民族事务委员会-首页

北京模特艺术发展促进会

暂无描述...

翰辉陶瓷 - 以匠心品质筑就东方美居

广东一线瓷砖品牌，广东豪门奢瓷陶瓷有限公司旗下品牌：翰辉陶瓷，深植于中国陶瓷艺术与文化的沃土之中，是一家集深厚历史底蕴与现代创新理念于一身的高端陶瓷品牌运营商。坐落于中国陶瓷之都——广东，这里不仅是全球陶瓷产业的璀璨明珠，更是创新与美学的交汇点。豪门奢瓷，以其对品质的极致追求和对设计的独到见解，在激烈的市场竞争中脱颖而出，成为了行业内一颗耀眼的明星。

不锈钢深井泵,井用潜水泵,水冷式屏蔽潜水电机,智能静音泵,立式多级离心泵,浙江力士霸泵业有限公司

浙江力士霸泵业有限公司（原金华市力士霸水泵厂、金华市金力士泵业有限公司），专业生产工业及民用中高档深井泵、不锈钢潜水泵、不锈钢深井泵、不锈钢喷泉泵（喷泉专用泵）、井用潜水泵、不锈钢潜水电泵、水冷式屏蔽潜水电机、充油潜水电机、智能静音泵的企业，产品主要应用于农林灌溉、生活取水、工程建设、污水处理、市政供水、工业领域等领域。

浙江荣凯科技发展股份有限公司-2-氯烟酸,4-氯烟酸,6-氯烟腈,6-氯烟腈,6-氯烟酸-中国化工网

2-氯烟酸,4-氯烟酸,6-氯烟腈,6-氯烟腈,6-氯烟酸浙江荣凯科技发展股份有限公司-中国化工网

WestVac Biopharma

WestVacBiopharmaisfoundedbyAcademicianWeiYuquanfromWestChinaHospitalofSichuanUniversity,togetherwith10scientistsfromStateKeyLaboratoryofBiotherapy(SKLB).ItsheadquarterislocatedintheInternationalBio-Town,Chengdu.TheCEOofWestVacBiopharmaisProf.WeiYuquan,whoistheAcademicianofChineseAcademyofSciencesaswellastheDirectorofStateKeyLaboratoryofBiotherapy.WestVaciscommittedtoexploringthelatestbiotherapytechnologiesformajordiseases,includinginfectiousdiseases,malignanttumors,cardiovasculardiseases,andsoon.IthasattachedgreatimportanceintheResearchandDevelopment(R&D)ofCOVID-19vaccineespeciallyandbuildingaCOVID-19vaccineproductionplatform.StateKeyLaboratoryofBiotherapy(SKLB)wasestablishedbytheMinistryofSciencesandTechnologyofChinain2005andbecameoneoftheNationalR&DPlatformsforNovelDrugsfoundedbytheMinistriesofSciencesandTechnologyaswellasthatofHealthofChinain2008.ItisalsosupportedbyNationalCollaborativeInnovationProgramandhasbecometheNationalCollaborativeInnovationCenterforBiotherapysince2013.WestChinaHospitalofSichuanUniversity，foundedin1892,istheNationalCenterforDiagnosisandTreatmentofSevereandCriticalDiseasesinWesternChina.Itisalsotheworld’slargestcomprehensivehospitalcomplexlocatedinonecampusarea.RelyingonthemedicalresourcesofStateKeyLaboratoryofBiotherapyandWestChinaMedicalCenter,WestVachasadoptedrecombinantproteinmethodologytodeveloptheCOVID-19vaccine.Becauseofthesafetyoftheproteinvaccine,itisalsotheonlyCOVID-19vaccineapprovedfortheuseinchildrenover3yearsoldinChina.ThevaccinewasapprovedbytheNationalMedicalProductsAdministrationforclinicaltrialsonAugust21,2020.PhaseI/IIclinicaltrialshavebeencompleted,andphaseIIIclinicaltrialsarebeingcarriedoutinNepal,Kenya,Japanandothercountries.Thevaccinetargetsthespikeproteinbindingdomain(S-RBD)ofSARS-CoV-2,producingneutralizingantibodiestoblockCOVID-19infectionofhumancells.TheresultwaspublishedonNature,theworld’sfamousscientificjournalonJuly29th,2020.IthasalsobeenthefirstpaperofCOVIDvaccinepublishedbyNaturesincethepandemicoutbreak.TheS-RBDgeneoftheCOVID-19virusisintroducedintotheinsectcells,whichwereusedasafactorytoproducehigh-qualityrecombinantvaccineproteinandthendoesrefinedpurification.Suchtechnologyiseasytobemass-producedandbroughttothemarket.WestVacBiopharmaiscommittedtobecomingtheworld`sleadingvaccineandimmunotherapyplatform.